Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach

References

• Worldometer. COVID-19 Coronavirus pandemic. Available from: https://www.worldometers.info/coronavirus. Accessed April 3, 2020.
   Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
   PubMed Web of Science ®Google Scholar
• Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924
   PubMed Web of Science ®Google Scholar
• Mehta D, Miller C, Arnold DL, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice. Neurology. 2019;92(15):e1724–e1738. doi:10.1212/WNL.0000000000007262
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–1516. doi:10.1016/S0140-6736(13)61048-X
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125(Suppl 2):S3–23. doi:10.1016/j.jaci.2009.12.980
   PubMed Web of Science ®Google Scholar
• Carroll MC. Complement and humoral immunity. Vaccine. 2008;26(Suppl 8):I28–33. doi:10.1016/j.vaccine.2008.11.022
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Implementation of mitigation strategies for communities with local COVID-19 transmission. Available from: https://www.cdc.gov/coronavirus/2019-ncov/downloads/community-mitigation-strategy.pdf. Accessed March 12, 2020.
   Google Scholar
• Montgomery S, Hillert J, Bahmanyar S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol. 2013;20(8):1153–1160. doi:10.1111/ene.12130
   PubMed Web of Science ®Google Scholar
• Tzelepis GE, McCool FD. Respiratory dysfunction in multiple sclerosis. Respir Med. 2015;109(6):671–679. doi:10.1016/j.rmed.2015.01.018
   PubMed Web of Science ®Google Scholar
• Piehl F. A changing treatment landscape for multiple sclerosis: challenges and opportunities. J Intern Med. 2014;275(4):364–381. doi:10.1111/joim.12204
   PubMed Web of Science ®Google Scholar
• Ferguson N, Laydon D, Nedjati Gilani G, et al. Report 9: impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. 2020.
   Google Scholar
• De Angelis F, John NA, Brownlee WJ. Disease-modifying therapies for multiple sclerosis. BMJ. 2018;363:k4674. doi:10.1136/bmj.k4674
   PubMed Web of Science ®Google Scholar
• Hong J, Tejada-Simon MV, Rivera VM, Zang YC, Zhang JZ. Anti-viral properties of interferon beta treatment in patients with multiple sclerosis. Mult Scler. 2002;8(3):237–242. doi:10.1191/1352458502ms794oa
   PubMed Web of Science ®Google Scholar
• Torkildsen Ø, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016;23(Suppl 1):18–27. doi:10.1111/ene.12883
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB multiple sclerosis study group. Neurology. 1993;43(4):655–661. doi:10.1212/WNL.43.4.655
   PubMed Web of Science ®Google Scholar
• Russell B, Moss C, Rigg A, Van Hemelrijck M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience. 2020;14:1023. doi:10.3332/ecancer.2020.1023
   PubMed Web of Science ®Google Scholar
• Winkelmann A, Loebermann M, Reisinger EC, Zettl UK. Multiple sclerosis treatment and infectious issues: update 2013. Clin Exp Immunol. 2014;175(3):425–438. doi:10.1111/cei.12226
   PubMed Web of Science ®Google Scholar
• Johnson KP. Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosis. Ther Clin Risk Manag. 2010;6:153–172. doi:10.2147/TCRM.S6743
   PubMed Web of Science ®Google Scholar
• Gold R, Wolinsky J. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011;124(2):75–84. doi:10.1111/j.1600-0404.2010.01444.x
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74(6):659–674. doi:10.1007/s40265-014-0212-x
   PubMed Web of Science ®Google Scholar
• Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS. Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: pooled analysis of clinical trials. Mult Scler J. 2019;1352458519851981.
   Web of Science ®Google Scholar
• Sanofi G. AUBAGIO 14 mg film-coated tablets. Available from: https://www.medicines.org.uk/emc/product/5244/smpc. Accessed October 31, 2019.
   Google Scholar
• Oh J, O’Connor PW. An update of teriflunomide for treatment of multiple sclerosis. Ther Clin Risk Manag. 2013;9:177–190. doi:10.2147/TCRM.S30947
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Ramanathan M, Hagemeier J, et al. Teriflunomide’s effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis. Mult Scler Relat Disord. 2019;36:101388. doi:10.1016/j.msard.2019.101388
   PubMed Web of Science ®Google Scholar
• Able RA, Turner TJ, Chavin J, Mandel M Teriflunomide may modulate viral replication via its impact on host pyrimidine metabolism. Paper presented at: MULTIPLE SCLEROSIS JOURNAL; 2018.
   Google Scholar
• Peng H, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem. 2012;287(33):28017–28026. doi:10.1074/jbc.M112.383380
   PubMed Web of Science ®Google Scholar
• Tan L, Wang Q, Zhang D, et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther. 2020;5(1):1–3. doi:10.1038/s41392-019-0089-y
   PubMed Web of Science ®Google Scholar
• Mirabella M, Prosperini L, Lucchini M, et al. Safety and efficacy of dimethyl fumarate in multiple sclerosis: an Italian, multicenter, real-world study. CNS Drugs. 2018;32(10):963–970. doi:10.1007/s40263-018-0543-3
   PubMed Web of Science ®Google Scholar
• Sejbaek T, Nybo M, Petersen T, Illes Z. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord. 2018;24:42–46. doi:10.1016/j.msard.2018.05.007
   PubMed Web of Science ®Google Scholar
• Fox RJ, Chan A, Gold R, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6(3):220–229. doi:10.1212/CPJ.0000000000000238
   PubMedGoogle Scholar
• Alasdair Coles and the MS Advisory Group, in consultation with Dr Ming Lim on behalf of paediatric MS group, Prof Gavin Giovannoni on behalf of MS Academy and Phillip Anderson for the MS Society ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a Coronavirus epidemic. Available from: https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf. Accessed March 11, 2020.
   Google Scholar
• European Medicines Agency. Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. Available from: https://www.ema.europa.eu/en/news/updated-recommendations-minimise-risk-rare-brain-infection-pml-tecfidera. Accessed October 23, 2015.
   Google Scholar
• The coronavirus and MS – global advice. Available from: https://www.msif.org/news/2020/02/10/the-coronavirus-and-ms-what-you-need-to-know/. Accessed April 6, 2020.
   Google Scholar
• Soelberg Sorensen P. Safety concerns and risk management of multiple sclerosis therapies. Acta Neurol Scand. 2017;136(3):168–186. doi:10.1111/ane.12712
   PubMed Web of Science ®Google Scholar
• Winkelmann A, Loebermann M, Reisinger EC, Hartung H-P, Zettl UK. Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol. 2016;12(4):217. doi:10.1038/nrneurol.2016.21
   PubMed Web of Science ®Google Scholar
• Grebenciucova E, Pruitt A. Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep. 2017;17(11):88. doi:10.1007/s11910-017-0800-8
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi:10.1056/NEJMoa0907839
   PubMed Web of Science ®Google Scholar
• Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag. 2013;9:73–85. doi:10.2147/TCRM.S17426
   PubMed Web of Science ®Google Scholar
• Francis G, Kappos L, O’Connor P, et al. Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler. 2014;20(4):471–480. doi:10.1177/1352458513500551
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Kantor D, Pawate S, et al. Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurol Clin Pract. 2018;8(2):102–107. doi:10.1212/CPJ.0000000000000434
   PubMedGoogle Scholar
• Wang N. Fingolimod in COVID-19. Available from: https://clinicaltrials.gov/ct2/show/NCT04280588. Accessed February 21, 2020.
   Google Scholar
• Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol. 2012;69(2):262–264. doi:10.1001/archneurol.2011.1057
   PubMedGoogle Scholar
• Ghezzi A, Rocca M, Baroncini D, et al. Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients. J Neurol. 2013;260(1):327–329. doi:10.1007/s00415-012-6744-7
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis. 2008;5(1):16–22. doi:10.1159/000109933
   PubMed Web of Science ®Google Scholar
• Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;90(17):777–788. doi:10.1212/WNL.0000000000005347
   PubMed Web of Science ®Google Scholar
• Luna G, Alping P, Burman J, et al. Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol. 2019;77(2):184–191.
   Web of Science ®Google Scholar
• González-Suarez I, Rodríguez de Antonio L, Orviz A, Rodríguez de Antonio L, Orviz A, et al. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation. Brain Behav. 2017;7(4):e00671–e00671. doi:10.1002/brb3.671
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Cladribine to treat relapsing forms of multiple sclerosis. Neurotherapeutics. 2017;14(4):874–887. doi:10.1007/s13311-017-0573-4
   PubMed Web of Science ®Google Scholar
• Cook S, Leist T, Comi G, et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult Scler Relat Disord. 2019;29:157–167. doi:10.1016/j.msard.2018.11.021
   PubMed Web of Science ®Google Scholar
• Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020;94(22):949–952. doi:10.1212/WNL.0000000000009507
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456–473. doi:10.1016/j.ctrv.2005.05.007
   PubMed Web of Science ®Google Scholar
• Juto A, Fink K, Al Nimer F, Piehl F. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord. 2020;37:101468. doi:10.1016/j.msard.2019.101468
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Cree BAC, Hauser SL. Ocrelizumab and other CD20(+) B-cell-depleting therapies in multiple sclerosis. Neurotherapeutics. 2017;14(4):835–841. doi:10.1007/s13311-017-0557-4
   PubMed Web of Science ®Google Scholar
• Hamdy SM, Abdel-Naseer M, Shalaby NM, et al. Characteristics and predictors of progression in an Egyptian multiple sclerosis cohort: a multicenter registry study. Neuropsychiatr Dis Treat. 2017;13:1895–1903. doi:10.2147/NDT.S140869
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Burman J, et al. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial. JAMA. 2019;321(2):165–174. doi:10.1001/jama.2018.18743
   PubMed Web of Science ®Google Scholar
• Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev. 2004;(2):Cd003208.
   PubMedGoogle Scholar
• Markovic–Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon β-1b. Neurology. 2003;60(11):1849–1851. doi:10.1212/01.WNL.0000071218.34009.AF
   PubMed Web of Science ®Google Scholar
• Alberts DS, Einspahr JG, Struck R, et al. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Invest New Drugs. 1984;2(2):141–148. doi:10.1007/BF00232343
   PubMed Web of Science ®Google Scholar
• Lennard L. TPMT in the treatment of Crohn’s disease with azathioprine. Gut. 2002;51(2):143–146. doi:10.1136/gut.51.2.143
   PubMed Web of Science ®Google Scholar
• Pfizer Canada. Product monograph Prmethotrexate injection USP. Available from: https://www.pfizer.ca/sites/default/files/201908/Methotrexate_Injection_PM_E_224776_08July2019.pdf. Accessed July 8 2019.
   Google Scholar
• Orlicka K, Barnes E, Culver EL. Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis. 2013;4(4):167–185. doi:10.1177/2040622313485275
   PubMedGoogle Scholar
• Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev. 1983;10(2):103–115. doi:10.1016/0305-7372(83)90008-7
   PubMed Web of Science ®Google Scholar
• Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev. 1983;10:3–11. doi:10.1016/0305-7372(83)90016-6
   PubMed Web of Science ®Google Scholar
• Fidler JM, DeJoy SQ, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol. 1986;137(2):727–732.
   PubMed Web of Science ®Google Scholar
• Anstey AV, Wakelin S, Reynolds N. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004;151(6):1123–1132. doi:10.1111/j.1365-2133.2004.06323.x
   PubMed Web of Science ®Google Scholar
• Hale G, Waldermann H. From Laboratory to Clinic: The Story of CAMPATH-1. Clifton. NJ: Humana Press; 2000.
   Google Scholar
• Hartung H-P, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing–remitting multiple sclerosis. Mult Scler J. 2015;21(1):22–34. doi:10.1177/1352458514549398
   PubMed Web of Science ®Google Scholar
• Hu Y, Turner MJ, Shields J, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–270. doi:10.1111/j.1365-2567.2009.03115.x
   PubMed Web of Science ®Google Scholar
• Brett S, Baxter G, Cooper H, Johnston J, Tite J, Rapson N. Repopulation of blood lymphocyte sub‐populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH‐1H. Immunology. 1996;88(1):13–19. doi:10.1046/j.1365-2567.1996.d01-650.x
   PubMed Web of Science ®Google Scholar
• Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002;100(5):1715–1720.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston D, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–1801.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled Phase 3 trial. Lancet. 2012;380(9856):1819–1828. doi:10.1016/S0140-6736(12)61769-3
   PubMed Web of Science ®Google Scholar
• Coles AJ Alemtuzumab treatment of multiple sclerosis. Paper presented at: Seminars in neurology; 2013.
   Google Scholar
• Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332–3342. doi:10.1002/eji.200535075
   PubMed Web of Science ®Google Scholar
• Zhang X, Tao Y, Chopra M, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing–remitting multiple sclerosis. J Immunol. 2013;191(12):5867–5874. doi:10.4049/jimmunol.1301926
   PubMed Web of Science ®Google Scholar
• Heidt S, Hester J, Shankar S, Friend PJ, Wood K. B cell repopulation after alemtuzumab induction—transient increase in transitional B cells and long‐term dominance of naïve B cells. Am J Transplant. 2012;12(7):1784–1792. doi:10.1111/j.1600-6143.2012.04012.x
   PubMed Web of Science ®Google Scholar
• Coles A, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology. 2012;78(14):1069–1078. doi:10.1212/WNL.0b013e31824e8ee7
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829–1839. doi:10.1016/S0140-6736(12)61768-1
   PubMed Web of Science ®Google Scholar
• Wray S, Arnold D, Cohen J, Coles A, Fox E, Hartung H Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. Paper presented at: Consortium of Multiple Sclerosis Centers Annual Meeting; 2013; Orlando, FL, USA.
   Google Scholar
• Brownlee WJ, Chataway J. Opportunistic infections after alemtuzumab: new cases of norcardial infection and cytomegalovirus syndrome. Mult Scler J. 2017;23(6):876–877. doi:10.1177/1352458517693440
   PubMed Web of Science ®Google Scholar
• Gallo P, Centonze D, Marrosu MG. Alemtuzumab for multiple sclerosis: the new concept of immunomodulation. Mult Scler Demyelinat Dis. 2017;2(1):7. doi:10.1186/s40893-017-0024-4
   Google Scholar
• Berkovich R. Treatment of acute relapses in multiple sclerosis. Transl Neuroimmunol Mult Scler. 2016;307–326.
   Google Scholar
• Lechner-Scott J, Kappos L, Hofman M, et al. Can the expanded disability status scale be assessed by telephone? Mult Scler J. 2003;9(2):154–159. doi:10.1191/1352458503ms884oa
   PubMed Web of Science ®Google Scholar
• Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS working group updated recommendations. Can J Neurol Sci. 2013;40(3):307–323. doi:10.1017/S0317167100014244
   PubMed Web of Science ®Google Scholar
• Chataway J, Porter B, Riazi A, et al. Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. Lancet Neurol. 2006;5(7):565–571. doi:10.1016/S1474-4422(06)70450-1
   PubMed Web of Science ®Google Scholar
• Lević Z, Micić D, Nikolić J, et al. Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. J Endocrinol Invest. 1996;19(1):30–34. doi:10.1007/BF03347855
   PubMed Web of Science ®Google Scholar
• Perumal J, Caon C, Hreha S, et al. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol. 2008;15(7):677–680. doi:10.1111/j.1468-1331.2008.02146.x
   PubMed Web of Science ®Google Scholar
• Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ. 2015;187(4):257–264. doi:10.1503/cmaj.130375
   PubMed Web of Science ®Google Scholar
• Elovaara I, Kuusisto H, Wu X, Rinta S, Dastidar P, Reipert B. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol. 2011;34(2):84–89. doi:10.1097/WNF.0b013e31820a17f3
   PubMed Web of Science ®Google Scholar
• Cao W, Liu X, Bai T, et al.High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus disease 2019. Paper presented at: Open Forum Infectious Diseases; 2020.
   Google Scholar
• Zhao X, Zhang B, Li P, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv. 2020.
   Google Scholar
• Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(1):108. doi:10.1186/s13054-020-2833-7
   PubMed Web of Science ®Google Scholar
• Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–677. doi:10.1016/S1473-3099(20)30243-7
   PubMed Web of Science ®Google Scholar
• Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
   PubMed Web of Science ®Google Scholar
• Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18. doi:10.18332/tid/119324
   Web of Science ®Google Scholar
• Nelson RE, Xie Y, DuVall SL, et al. Multiple sclerosis and risk of infection-related hospitalization and death in US veterans. Int J MS Care. 2015;17(5):221–230. doi:10.7224/1537-2073.2014-035
   PubMedGoogle Scholar
• MS and corona care and support. Available from: https://www.mssociety.org.uk/care-and-support/ms-and-coronavirus-care-and-support. Accessed April 3, 2020.
   Google Scholar
• Green JR, Yunusova Y, Kuruvilla MS, et al. Bulbar and speech motor assessment in ALS: challenges and future directions. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(7–8):494–500. doi:10.3109/21678421.2013.817585
   PubMed Web of Science ®Google Scholar
• Luo Y, Yin K. Management of pregnant women infected with COVID-19. Lancet Infect Dis. 2020;20(5):513–514. doi:10.1016/S1473-3099(20)30191-2
   PubMed Web of Science ®Google Scholar
• Dietz W, Santos‐Burgoa C. Obesity and its Implications for COVID‐19 mortality. Obesity. 2020;28(6):1005. doi:10.1002/oby.22818
   PubMed Web of Science ®Google Scholar
• Case definition of COVID-19 infection. Available from: https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-novel-coronavirus-information-specific-audiences/covid-19-novel-coronavirus-resources-health-professionals/case-definition-covid-19-infection. Accessed April 3, 2020.
   Google Scholar
• Adams JG, Walls RM. Supporting the health care workforce during the COVID-19 global epidemic. JAMA. 2020;323(15):1439. doi:10.1001/jama.2020.3972
   PubMed Web of Science ®Google Scholar
• Syed YY. Ocrelizumab: a review in multiple sclerosis. CNS Drugs. 2018;32(9):883–890. doi:10.1007/s40263-018-0568-7
   PubMed Web of Science ®Google Scholar
• Yamout B, Sahraian M, Bohlega S, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord. 2020;37:101459. doi:10.1016/j.msard.2019.101459
   PubMed Web of Science ®Google Scholar